中国肺癌杂志最新文献

{"title":"[Current Status of Multidisciplinary Team Consultation for Lung Cancer and Prospects under the Empowerment of Medical Large Models].","authors":"Yingxin Fu, Li Shan, Tingting Yu","doi":"10.3779/j.issn.1009-3419.2026.106.12","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.12","url":null,"abstract":"<p><p>Lung cancer ranks among malignant neoplasms with the highest incidence and mortality, and its diagnosis and treatment are complicated, requiring multidisciplinary participation. Multidisciplinary team (MDT) consultation is the core model for modern lung cancer management. By pooling the expertise of specialists from diverse disciplines, MDT develops optimal individualized treatment regimens for patients and markedly improves diagnostic and therapeutic quality as well as patient prognosis. This article systematically summarizes the organizational framework, standardized procedures and clinical value of lung cancer MDT, alongside key problems in its popularization including obstacles in data integration, inconsistent decision-making efficiency and imbalanced resource allocation. It elaborates on the innovative effect of new technologies represented by artificial intelligence large language models on conventional MDT modes, and analyzes their application value in high-efficiency integration of multimodal medical data, real-time evidence-based decision-making support, optimization of consultation procedures and resources, as well as precise individualized treatment, so as to furnish theoretical basis and development ideas for establishing a new-generation intelligent, efficient and precise lung cancer MDT platform.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"376-381"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of S100P in Lung Adenocarcinoma and Its Clinical Significance].","authors":"Ziyi Ding, Donghui Zhang, Nanyang Li, Kai Luo, Jiahao Chen, Binghui Ding, Qian Wang","doi":"10.3779/j.issn.1009-3419.2026.101.12","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.12","url":null,"abstract":"<p><strong>Background: </strong>Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC). Due to the lack of obvious symptoms and signs in the early stages, most patients are already in the middle or late stages at diagnosis. This makes treatment difficult and prognosis poor. Therefore, the identification of effective and specific biomarkers for lung cancer remains a focal area of research. So this study aimed to investigate the expression and clinical significance of S100 calcium-binding protein P (S100P) in LUAD.</p><p><strong>Methods: </strong>Tissue samples of LUAD (n=50), adjacent normal lung tissue (n=50), and benign inflammatory lesions (n=50) were collected from The Affiliated Cancer Hospital, Guangzhou Medical University, used as the LUAD group, normal group and benign group. Immunohistochemistry (SP method) was employed to detect the expression of S100P, C-C chemokine ligand 4 (CCL4), and cluster of differentiation 8 (CD8) proteins. Correlation analyses were carried out.</p><p><strong>Results: </strong>Database analysis (UALCAN, GEPIA2) identified S100P as an mRNA with high expression in LUAD. Immunohistochemistry demonstrated that the protein levels of S100P and CCL4 were significantly higher in lung tissues of the LUAD group compared to those in the normal group and benign group (all P<0.05). The area under the curve (AUC) of S100P for differentiating LUAD was 0.943. The expression of S100P showed no significant correlation with age, sex, tumor size, or degree of differentiation (all P>0.05). Correlation analysis revealed that S100P expression was moderately positively correlated with CCL4 (r=0.611, P<0.001), and positively correlated with CD8+ lymphocyte infiltration (r=0.461, P<0.001). CCL4 expression was also positively correlated with CD8+ infiltration (r=0.400, P<0.001).</p><p><strong>Conclusions: </strong>Database analysis indicates that S100P is highly expressed in LUAD and associated with a poor prognosis, making it a potential biomarker for the prognosis of LUAD. Clinical tissue analysis further shows that S100P expression is correlated with CD8+ lymphocyte infiltration in LUAD, suggesting that S100P can serve as a biomarker of lymphocyte infiltration and a potential predictor of the response to immune checkpoint inhibitors.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"348-360"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494958/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Surgical Management of Lung Cancer in Patients with Interstitial Lung Disease].","authors":"Yang Liu, Chuan Huang","doi":"10.3779/j.issn.1009-3419.2026.106.14","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.14","url":null,"abstract":"<p><p>Interstitial lung disease (ILD) is characterized by varying degrees of inflammation and fibrosis of the pulmonary interstitium, posing a significant threat to human health. Patients with ILD have a significantly higher risk of developing lung cancer compared to the general population, which has led to growing clinical attention to the condition of ILD combined with lung cancer (ILD-LC). Nowadays, surgical intervention remains the primary treatment option for patients with ILD-LC. However, how to formulate individualized surgical strategies for this patient population represents a critical challenge in clinical practice. Additionally, patients with ILD-LC are prone to postoperative acute exacerbation of ILD (AE-ILD), which is often challenging to detect at an early stage and severely compromises prognosis. Against this background, this article systematically reviews key aspects of ILD-LC, including differential diagnosis, surgical strategies, and perioperative management, with particular emphasis on the recognition and management of postoperative AE-ILD. It aims to provide a reference for the surgical treatment of ILD-LC and to outline directions for future research.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"382-389"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494959/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Radiotherapy for SMARCA4-deficient Pulmonary Neoplasms: \u2029Efficacy and Related Parameter Analysis].","authors":"Yu Gu, Ruxi Gao, Xingwen Fan, Xiaoxiao Ge","doi":"10.3779/j.issn.1009-3419.2026.102.15","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.15","url":null,"abstract":"<p><strong>Background: </strong>SMARCA4-deficient pulmonary neoplasms have emerged as a major focus of lung cancer research in recent years. This subtype is characterized by aggressive behavior and poor prognosis. However, radiotherapy-related studies in this population remain scarce, and evidence is lacking regarding the optimal selection of radiotherapy parameters and the sequencing of combination with immunotherapy. The present study aimed to evaluate the efficacy of radiotherapy in these tumors and to explore the prognostic value of radiotherapy parameters.</p><p><strong>Methods: </strong>Clinical data of 88 patients with SMARCA4-deficient pulmonary neoplasms were retrospectively analyzed. Patients were divided into a radiotherapy group (n=20) and a non-radiotherapy group (n=68). Overall survival (OS) was compared between groups using the Kaplan-Meier method. Subgroup analyses were performed for radiotherapy site, biological equivalent dose (BED), fractionation mode, and the timing of radiotherapy combined with immunotherapy.</p><p><strong>Results: </strong>The radiotherapy group had a lower proportion of patients aged ≥60 years (25.0% vs 66.2%, P<0.001) and a higher proportion receiving immunotherapy (65.0% vs 33.8%, P=0.013) compared with the non-radiotherapy group. The median OS was not reached in the radiotherapy group, which was significantly superior to that in the non-radiotherapy group (22.9 mon, P=0.048). Among patients receiving radiotherapy, those who also received immunotherapy had a significantly longer median OS than those receiving radiotherapy alone. No statistically significant differences in OS were observed among subgroups stratified by radiotherapy site, BED, fractionation schedule or timing.</p><p><strong>Conclusions: </strong>Radiotherapy effectively improves OS in SMARCA4-deficient lung tumors, with synergistic potential when combined with immunotherapy. The lack of prognostic impact of radiotherapy parameters supports regimen simplification, while the timing of combined therapy needs refinement. These exploratory results lay a critical foundation for future large‑sample confirmatory studies.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"370-375"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Pleural Well-differentiated Papillary Mesothelial Tumor Presenting with \u2029Recurrent Pneumothorax and Pleural Effusion: A Case Report].","authors":"Zhe Li, Fanyi Kong, Bo Yang, Tianrun Song, Shuai Zhao, Xiang Song","doi":"10.3779/j.issn.1009-3419.2026.101.11","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.11","url":null,"abstract":"<p><p>Well-differentiated papillary mesothelial tumor (WDPMT) is a rare neoplasm characterized by a distinct papillary architecture, bland cytological features, and a propensity for superficial spread without stromal invasion. We herein report the diagnosis and management of a patient with pleural WDPMT presenting predominantly with recurrent spontaneous pneumothorax and pleural effusion, along with a review of the current literature on this entity. The patient was a 58-year-old female who presented with a two-week history of chest tightness and dyspnea on a background of recurrent spontaneous pneumothorax and pleural effusion over the preceding seven years. She had experienced four episodes of recurrence during that period and denied any history of asbestos exposure. Thoracoscopic exploration revealed pulmonary bullae, pleural effusion and pneumothorax, pleural thickening, and scattered grayish-white nodules on both the visceral and parietal pleura. Histopathological examination of the pleural nodule biopsy confirmed the diagnosis of WDPMT. Based on the features of this case and a review of the literature, clinicians should be aware that WDPMT may present with the atypical manifestation of recurrent spontaneous pneumothorax accompanied by pleural effusion.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"390-394"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494942/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinicopathological Characteristics of ROS1-positive \u2029Non-small Cell Lung Cancer Based on Next-generation Sequencing].","authors":"Lina Gao, Li Sun, Weihua Li, Jiali Mu, Jinduo Qiao, Lei Guo","doi":"10.3779/j.issn.1009-3419.2026.106.13","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.13","url":null,"abstract":"<p><strong>Background: </strong>C-ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) gene fusion-positive non-small cell lung cancer (NSCLC) is a high-risk subtype of lung cancer, and the accurate identification of this specific subtype is critically important. This study systematically analyzes the concordance between the results of next-generation sequencing (NGS), immunohistochemistry (IHC), and fluorescence in situ hybridization (FISH) to validate the clinical value of IHC as an initial screening tool for ROS1 fusions.</p><p><strong>Methods: </strong>Patients with NSCLC diagnosed at Cancer Hospital, Chinese Academy of Medical Sciences between November 1, 2020 and November 30, 2022 were enrolled. All cases were tested for ROS1 gene fusion via NGS, re-examined with hematoxylin-eosin (HE) staining, and ROS1 protein expression and gene breakage were detected using IHC and FISH. The results of the three detection methods and their correlation with clinicopathological characteristics were compared.</p><p><strong>Results: </strong>22 were detected as ROS1 fusion-positive among 770 NSCLC cases. Histologically, all were lung adenocarcinoma, predominantly poorly differentiated. The main growth patterns included solid, acinar, and papillary types. IHC detection showed positive expression of ROS1 protein in all 22 cases, including 14 cases (63.6%) with strong diffuse positivity, resulting in a positive concordance rate of 100.0%. FISH detection revealed a typical isolated signal pattern in 16 cases, with a positive concordance rate of 72.7%. The overall concordance rate among NGS, IHC, and FISH was 72.7%.</p><p><strong>Conclusions: </strong>ROS1 fusion-positive NSCLC exhibits characteristic clinicopathological features. In ROS1 fusion-positive cases confirmed by NGS, IHC serves as a highly sensitive tool with 100.0% sensitivity, suggesting its potential as an initial screening method, but its specificity still needs further verification. NGS testing is recommended as a priority in cases with strong ROS1 IHC positivity. When strong IHC positivity is observed alongside atypical FISH signals, NGS becomes a key technique for confirmation and precise identification of fusion partners and breakpoints. An integrated diagnostic strategy combining histomorphological evaluation, IHC preliminary screening, and NGS validation facilitates accurate diagnosis of ROS1-positive lung cancer, thereby guiding clinical targeted therapy implementation.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 5","pages":"361-369"},"PeriodicalIF":0.0,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13494946/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148449899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy \u2029for SCLC].","authors":"","doi":"10.3779/j.issn.1009-3419.2026.106.10","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.10","url":null,"abstract":"<p><p>Small cell lung cancer (SCLC), characterized by high aggressiveness, early metastasis, and poor prognosis, has long been a major challenge in lung cancer treatment. In recent years, the advent of immune checkpoint inhibitors (ICIs) has significantly improved overall survival in patients with SCLC and has become a new standard of care; however, substantial room for further improvement in clinical outcomes remains. As an emerging T cell-targeted immunotherapy, delta-like ligand 3-T cell engager (DLL3-TCE) precisely directs T cells to attack tumor cells and have demonstrated breakthrough potential in the treatment of SCLC. Tarlatamab, a representative agent in this class, has been approved for clinical use, and multiple TCE agents are currently under clinical development. Although DLL3-TCE shows promising prospects in the clinical management of SCLC, as a novel therapeutic modality, many clinicians still lack an in-depth understanding of their mechanisms of action, appropriate patient populations, and clinical management. To standardize the clinical application of DLL3-TCE in China, the Small Cell Lung Cancer Expert Committee of the Chinese Society of Clinical Oncology convened a consensus panel to develop the Chinese Expert Consensus on Delta-like Ligand 3-T Cell Engager Therapy for SCLC based on evidence-based medicine and expert practical experience, with the aim of providing standardized guidance for the clinical use of DLL3-TCE agents.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 4","pages":"233-250"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Advances in ctDNA-MRD Monitoring in Local Treatment \u2029for Non-small Cell Lung Cancer].","authors":"Zeyu Li, Yufei Wang, Yongkun Wu, Zhanlin Guo","doi":"10.3779/j.issn.1009-3419.2026.102.11","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.11","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) remains at risk of recurrence after local treatment, and early identification of molecular residual disease before radiological progression is an important issue in risk stratification. Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) monitoring provides a promising molecular tool for recurrence risk assessment, response evaluation, and subsequent treatment stratification. However, surgery, thermal ablation, definitive chemoradiotherapy, and stereotactic body radiotherapy differ in tumor burden changes, tissue injury, and DNA release and clearance, leading to uncertainty regarding sampling time points, result interpretation, and clinical utility. This review summarizes recent advances in ctDNA-MRD monitoring after local treatment for NSCLC, focusing on ctDNA kinetics, candidate assessment windows, assay platform differences, prognostic value, and translational limitations in perioperative, thermal ablation, and radiotherapy settings. Current evidence suggests that perioperative ctDNA-MRD status is associated with pathological response, recurrence risk, and survival outcomes. In contrast, direct evidence after thermal ablation and stereotactic body radiotherapy remains limited, and proposed sampling time points should be regarded as candidate assessment windows rather than standardized recommendations. Further studies with standardized sampling, assay validation, and prospective interventional designs are needed to clarify the clinical value of ctDNA-MRD in adjuvant treatment selection, intensified surveillance, and individualized management.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 4","pages":"294-301"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314045/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment].","authors":"Liyan Liao, Xiaohong Li","doi":"10.3779/j.issn.1009-3419.2026.101.09","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.09","url":null,"abstract":"<p><p>Epidermal growth factor receptor (EGFR) gene mutations are the most common driver mutations in non-small cell lung cancer (NSCLC). This article reports a case of a patient with EGFR-sensitive mutant lung adenocarcinoma who developed secondary transformation to small cell lung cancer (SCLC) and anaplastic lymphoma kinase (ALK) gene fusion following first-line Osimertinib therapy. This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment, suggesting that the two can coexist as dual drug resistance mechanisms. Re-biopsy combined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 4","pages":"310-314"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mechanisms of Macrophage Efferocytosis-driven Remodeling of Lung Cancer \u2029Microenvironment Structure and Angiogenesis and Prospects for Clinical Intervention].","authors":"Yu Qin, Hongmei Yue, Yongqing Wang, Zhangfan Zhu, Fan Yang","doi":"10.3779/j.issn.1009-3419.2026.101.08","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.08","url":null,"abstract":"<p><p>Lung cancer is one of the most prevalent and lethal malignant tumors worldwide. In recent years, immune checkpoint inhibitors have significantly improved the survival outcomes of some patients with advanced non-small cell lung cancer; however, primary and acquired resistance remain important barriers limiting their clinical efficacy. Research has revealed that structural remodeling of the tumor microenvironment (TME) is one of the key factors involved in immunotherapy resistance. Efferocytosis is an important process by which tumor-associated macrophages clear apoptotic cells. In the lung cancer TME, the high apoptotic cell burden can lead to persistent activation of efferocytosis. Studies have shown that sustained efferocytosis is not merely a process of cellular debris clearance, but can also induce metabolic reprogramming in macrophages, including dysregulated lipid metabolism and enhanced glycolysis, and promote the secretion of immunosuppressive and tissue-repair-related factors. These changes further promote pathological angiogenesis, activation of cancer-associated fibroblasts, and excessive extracellular matrix deposition, thereby driving structural remodeling of the TME and forming an immune-excluded microenvironment characterized by vascular abnormalities and stromal fibrosis. This process restricts effector T-cell infiltration and impairs the efficacy of immune checkpoint inhibitors. This review describes the molecular mechanisms of macrophage efferocytosis in the lung cancer TME, focusing on its regulatory roles in metabolic reprogramming, pathological angiogenesis, and stromal fibrosis, and discusses potential therapeutic strategies targeting efferocytosis-related signaling pathways and TME structural remodeling, aiming to provide new insights into overcoming immunotherapy resistance in lung cancer.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 4","pages":"286-293"},"PeriodicalIF":0.0,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13314051/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148253948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}